Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Some weight loss drugs may cause hair loss. While it’s typically a temporary side effect, it can affect your confidence.

A new study reveals that weight lost with GLP-1 drugs, such as semaglutide, is regained within a year after stopping ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

The drug coverage provision does not mention any specific drug by name, but it could include the GLP-1 agonists, such as ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

Prices are falling for the popular obesity treatments semaglutide (Wegovy) and tirzepatide (Zepbound), but steady access to the drugs remains challenging. The medications still amount to around $500 ...

Weight loss medications can reduce the efficacy of oral contraceptives. What to know before taking drugs like Ozempic, ...